Vistide Recall for Particulate Matter
Gilead Sciences Inc. voluntarily recalled one lot of Vistide (cidofovir injection) over a possible contamination with visible particulate matter.
The recall is for lot number B120217A, according to the Food and Drug Administration. The recalled product is clear, colorless, and supplied in clear glass vials. It is used in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.
Gilead said it is not currently aware of any complaint attributable to the particles.
The company has notified its distributors and customers by e-mail and recall letter of the issue. Gilead requests healthcare providers to examine the product before injecting and return any product with lot number B120217A.